Bayer Aktiengesellschaft

Bayer Healthcare Aktiengesellschaft

Bayeraktiengesellschaft

Arno Friedl

Frank Mauler

Reinhard Jork

Joachim Mittendorf

Michael Matzke

Verena V&ouml;hringer

Peter Spreyer

J&uuml;rgen Franz

J&uuml;rgen Dressel

J&ouml;rg Keldenich

Michael-Harold Rock

Joachim Schuhmacher

Siegfried Raddatz

Klaus-Helmut Mohrs

Joachim Schumacher

Jean-Marie-Viktor De Vry

Ervin Horv&agrave;th

Ervin Horvath

Karl-Heinz Schlemmer

Adrian Tersteegen

Martin Hendrix

Ervin Horv&aacute;th

Jean Marie Viktor De Vry

Irene Gerlach

Volker Hinz

David Brückner

Jean-Marie-Victor De Vry

Rudolf Schohe-Loop

Thomas Glaser

Hans-Georg Heine

Jörg Keldenich

Peter-Rudolf Seidel

Paul Naab

Marcus Bauser

Dagmar Karthaus

Nils Burkhardt

Jens-Kerim Ergüden

Dietmar Flubacher

Maria Niewöhner

Maria Niewöhner, Legal Representative

Jürgen Stoltefuss

Dagmar Schauss

Özkan Yalkinoglu

Wolfgang Kanhai

Thorsten Oliver Repp

The invention relates to new substituted imidazotriazines, processes for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of cancer and neurodegenerative disorders, in particular of Parkinson's disease and of schizophrenia.

Substituted imidazotriazines

The invention relates to new imidazotriazines, processes for their preparation, and their use for the production of medicaments for the treatment and/or prophylaxis of neurodegenerative disorders, in particular Parkinson's disease.

Imidazotriazines for use as phosphodiesterase inhibitors

The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

Arylsulphonamides and analogues

The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases

The present invention relates to novel amino acid esters of arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.

Aryl sulphonamide amino acid esters and analogues

The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

Use of known agonists of the central cannabinoid receptor CB1

Aryl sulphonamides and analogues

The present invention relates to new aryl ether sulphonamides and analogs, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.

The benzisothiazolyl-substituted aminomethylchromans are prepared either by substituting the corresponding unsubstituted aminomethylchromans on the amine nitrogen or reacting the corresponding benzisothiazolylalkylamines with appropriate activated methylchromans or reacting the amine nitrogen of aminomethylchroman first with an appropriately substituted alkine and then hydrogenating. The benzisothiazolyl-substituted aminomethylchromans can be used as active compounds in medicaments, in particular in medicaments for the treatment of disorders of the central nervous system.

Benzisothiazolyl-substituted aminomethylchromans

Growing community of inventors

Bergisch Gladbach, Germany

Arno Friedl